Daptomycin Injectable Recalled Due to Manufacturing Deviations
Accord Healthcare is recalling Daptomycin for Injection due to manufacturing practice deviations discovered during FDA inspection. No illnesses or injuries have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The hazard is based on manufacturing compliance deviations rather than a documented safety event, making this a precautionary recall without evidence of actual harm.
Plain-English summary
Accord Healthcare, Inc. is recalling Daptomycin for Injection, 500 mg per vial, due to Current Good Manufacturing Practice (CGMP) deviations discovered during an FDA inspection. The product (NDC 16729-435-05) is manufactured by Intas Pharmaceuticals Limited in Ahmedabad, India, and distributed by Accord Healthcare. This is a Class II recall affecting approximately 228,760 vials.
The recalled product was distributed throughout the United States, including Puerto Rico and Canada. Multiple production batches are involved, with expiration dates ranging from September 2023 through July 2025. The affected batch numbers are R2101282, R2101600, R2200002, R2200028, R2200116, R2200142, R2200152, R2200165, R2200190, and R2201042.
CGMP deviations indicate potential quality control or manufacturing process issues that could affect product safety or effectiveness. However, no illnesses or injuries related to this product have been reported to the FDA.
Patients currently taking Daptomycin should not discontinue treatment without consulting their healthcare provider. Healthcare facilities should quarantine affected vials and contact their pharmaceutical supplier for replacement product or further instructions.
The recalled product
- Product
- DAPTOMYCIN (DAPTOMYCIN)
- Brand
- DAPTOMYCIN
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug
- Affected units
- 228,760
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (15)
- Batches: R2101282
- Exp. Date 9/30/2023
- R2101600
- Exp. Date 11/30/2024
- R2200002
- R2200028
- R2200116
- R2200142
- R2200152
- Exp. Date 12/31/2024
- R2200165
- R2200190
- Exp. Date 1/31/2025
- R2201042
- Exp. Date 7/31/2025
UPCs (2)
- 0316729435055
- 316729435055
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 67 recalled by Accord Healthcare, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same brand · DAPTOMYCIN
- ModerateDaptomycin injection recalled due to manufacturing compliance deviations
FDA (Drugs) · 2023-03-08
- SevereMylan Recalls Daptomycin Injection Due to Particulate Matter
FDA (Drugs) · 2020-08-12
Same manufacturer · Accord Healthcare, Inc.
See all →- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19